MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/ijms27188317

Медицинская библиотека · International journal of molecular sciences · 2026

Features of Lipid Disorders in Cardiovascular-Kidney-Metabolic Syndrome.

Ceasovschih Alexandr, Şener Yusuf Ziya, Arici Mustafa, Cherska Mariia, Bianconi Vanessa, Ejubović Malik, Kotlyarov Stanislav, Ristovski Vladimir, Yetkin Ahmet, Golforoush Pelin, Storozhenko Tatyana, Barkas Fotios, Corlateanu Alexandru, Sivapalan Pradeesh, Gamezardashvili Tea, Gotto Antonio M, Sorodoc Laurentiu, Sorodoc Victorita

СтатьяОбзорПеревод в очереди

Аннотация

Cardiovascular-kidney-metabolic (CKM) syndrome is driven by the interplay of visceral adiposity, insulin resistance, chronic inflammation, oxidative stress, and progressive kidney dysfunction. These mechanisms generate a distinct atherogenic dyslipidaemic phenotype characterised by elevated triglycerides (TG), reduced high-density lipoprotein-cholesterol (HDL-C), increased apolipoprotein B (apoB)-containing lipoproteins, remnant cholesterol (RC) accumulation, small dense low-density lipoprotein (LDL) particles, and frequently elevated lipoprotein(a) [Lp(a)]. Such lipid abnormalities contribute to accelerated atherosclerosis and early renal deterioration. In turn, kidney dysfunction further amplifies lipid abnormalities. These pathways underscore the need for a timely and comprehensive lipid assessment using apoB, non-HDL-C, RC, and Lp(a) within the CKM framework. Effective lipid management is crucial for CKM syndrome treatment, with the potential to reduce residual cardiovascular and renal risk and improve long-term clinical outcomes. In this narrative review, we examine current evidence on the pathophysiological mechanisms underlying CKM-related dyslipidaemia and provide a practical framework for its assessment and management. Management requires a multimodal approach tailored to the patient's lipid phenotype and overall cardiovascular risk, incorporating a range of lipid-lowering strategies including statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, fibrates, icosapent ethyl, and emerging therapies targeting apoC-III, ANGPTL3, and Lp(a). Beyond lipid lowering, lifestyle interventions and cardiometabolic therapies such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and finerenone may provide complementary cardiometabolic and renal protection.

Для цитирования: Ceasovschih Alexandr, Şener Yusuf Ziya, Arici Mustafa, Cherska Mariia, Bianconi Vanessa, Ejubović Malik, Kotlyarov Stanislav, Ristovski Vladimir, Yetkin Ahmet, Golforoush Pelin, Storozhenko Tatyana, Barkas Fotios, Corlateanu Alexandru, Sivapalan Pradeesh, Gamezardashvili Tea, Gotto Antonio M, Sorodoc Laurentiu, Sorodoc Victorita. Features of Lipid Disorders in Cardiovascular-Kidney-Metabolic Syndrome.. International journal of molecular sciences. 2026. DOI: 10.3390/ijms27188317.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.